<?xml version="1.0" encoding="UTF-8"?>
<p id="Par113">Serious adverse events (SAEs) are defined as any untoward medical occurrences or effects that result in death; or are life threatening (at the time of the event); or require in-patient hospitalisation or prolongation of existing hospitalisation; or result in persistent or significant disability or incapacity; or result in a congenital anomaly or birth defect; or any other important medical event. For all participants who undergo R2, SAEs should be reported from the date of first dose of study drug until 60 days after the date of disease progression. For all participants who do not proceedÂ to R2, SAEs should be reported until 60 days after the last dose of study drug. Serious adverse reactions (SARs) are to be reported from registration throughout the trial.</p>
